✦ LIBER ✦

An outbreak of vancomycin-resistant Enterococcus faecium in liver transplant recipients

✍ Scribed by Dominguez, E A ;Davis, J C ;Langnas, A N ;Winfield, B ;Cavalieri, S J ;Rupp, M E

Publisher: Wiley (John Wiley & Sons)
Year: 1997
Tongue: English
Weight: 161 KB
Volume: 3
Category: Article
ISSN: 1074-3022
DOI: 10.1002/lt.500030605

No coin nor oath required. For personal study only.

✦ Synopsis

Vancomycin-resistant Enterococcus faecium (VREF) has become a significant nosocomial pathogen for immunosuppressed patients. During a 5-month period in 1993, 8 cases of invasive infection with VREF (7 with bacteremia) were identified in liver transplant recipients, half of whom were adults. Epidemiology and microbiology studies were designed to identify the source and to determine the risk factors for this infection. Overall mortality was 50% (3 adults and 1 child). Mortality in bacteremic patients was 57%. A casecontrol study showed that cases were more likely to have been treated with a third-generation cephalosporin or vancomycin and to have undergone more than four biliary tract procedures. Environmental surveillance cultures yielded only one VREF isolate from a rectal temperature probe, but this device was used in only 2 of the cases. Cultures from all surgery and radiology suites were negative. All VREF isolates were genotyped by contour-clamped homogenous electric field electrophoresis of chromosomal DNA restriction fragments. These studies showed that a single clone was responsible for the outbreak, although other clones could be detected in the hospital. After implementing strict contact isolation on the liver transplant unit, only 1 additional patient with VREF was identified during this outbreak. In conclusion, it was found that antibiotic use and biliary tract manipulation were risk factors for developing invasive infections with VREF after liver transplantation. Optimal treatment is still unclear but most likely includes a combination of two or more antibiotics. Prompt institution of infection control measures can preclude rapid spread of this nosocomial pathogen.

📜 SIMILAR VOLUMES

Vancomycin-resistant enterococci in live

Vancomycin-resistant enterococci in liver transplant recipients

✍ Robin Patel 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB

Background: Vancomycin-resistant Enterococcus (VRE) infection is emerging in the transplant population, and there is no effective antibiotic therapy available. The aims of this retrospective review were to (1) investigate the outcome of and (2) identify common characteristics associated with VRE inf

Long-term outcome of mycophenolate mofet

Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients

✍ Marion Margaret Aw; Anita Verma; Mohamed Rela; Nigel Heaton; Giorgina Mieli-Verg 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

Mycophenolate mofetil (MMF) has been used to rescue liver allografts with steroid-resistant rejection (SRR). However, the long-term outcome of these patients is not known. This study evaluates the long-term outcome of MMF rescue therapy for SRR in pediatric liver allograft recipients. Twenty-six chi

Microbial epidemiology and outcome of bl

Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: An analysis of 259 episodes

✍ Frédéric Bert; Beatrice Larroque; Catherine Paugam-Burtz; Sylvie Janny; Francois 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB

Bloodstream infections (BSIs) are a major cause of mortality in liver transplant recipients. The incidence, microbiology, and outcome of BSIs in the first year after liver transplantation were analyzed in 704 patients who underwent transplantation at a single center between 1997 and 2007. BSIs occur

An assessment of interactions between he

An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance

✍ Atul Humar; Kenneth Washburn; Richard Freeman; Carlos V. Paya; Houria Mouas; Emm 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

Hepatitis C virus (HCV) has been proposed to have immunomodulatory effects in transplant recipients and may promote herpesvirus reactivation. To assess this, we compared the incidence of herpesvirus reactivation in HCV-positive and HCVnegative liver transplant recipients. Quantitative viral load tes

Hepatic steatosis at 1 year is an additi

Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus

✍ Danielle Brandman; Andrea Pingitore; Jennifer C. Lai; John P. Roberts; Linda Fer 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

Recurrent hepatitis C virus (HCV) is the most common cause of graft loss for HCV-infected recipients of liver transplantation (LT). Diabetes mellitus (DM) has been associated with increased rates of fibrosis progression, but whether steatosis affects post-LT outcomes independently of DM is unclear.